Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Terminated 3Withdrawn 1Unknown 1Suspended 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Trastuzumab 2Taxes 2Paclitaxel 2Fluorouracil 2Cyclophosphamide 2trastuzumab biosimilar HLX02 1tivozanib 1taletrectinib 1palbociclib 1eribulin 1atezolizumab 1Tomography, Optical Coherence 1Testosterone Propionate 1Testosterone 1Tamoxifen 1Tablets 1Specimen Handling 1Receptors, Chimeric Antigen 1Radiotherapy 1PF-05280014 1Ontruzant 1Ogivri 1Neoadjuvant Therapy 1Methotrexate 1Mastectomy, Segmental 1Lisaftoclax 1Interpersonal Psychotherapy 1Interleukin-2 1Injections 1G(M1) Ganglioside 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Breast Neoplasms × trastuzumab biosimilar HLX02 × Clear all
NCT04120246 2024-07-10

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Veana Therapeutics

Phase 1 Suspended
24 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡